Unrelated Donor Marrow (BMT) or Cord Blood Transplantation (UCBT) for Thalassemia Major after Reduced Intensity Conditioning (URTH Trial Extension)
Shalini Shenoy(Washington University in St. Louis), Alexis A. Thompson(Children's Hospital of Philadelphia), Ellis J. Neufeld(St. Jude Children's Research Hospital), Kimberly A. Kasow(University of North Carolina at Chapel Hill), Kamar Godder(Miami Children's Hospital), Mark C. Walters(UCSF Benioff Children's Hospital), Allistair Abraham(Children's National), James A. Connelly(Michigan Center for Translational Pathology), Martin Andreánsky(University of Miami Health System), Sonali Chaudhury(Northwestern University), Alexander Ngwube(Children's Cancer Center), Janet L. Kwiatkowski(Children's Hospital of Philadelphia), Ann E. Haight, Sandeep Soni(Lucile Packard Children's Hospital), Ka Wah Chan(Methodist Children’s Hospital), Michael L. Nieder(Rainbow Babies & Children's Hospital), David Delgado(Indiana University Hospital), Suhag Parikh(Emory University), Gregory A. Hale(Johns Hopkins University), Michael A. Pulsipher(Primary Children's Hospital)
Cited by 0
Related Papers
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
|New England Journal of Medicine|2018|5.7k
Integrative Clinical Sequencing in the Management of Refractory or Relapsed Cancer in Youth
|JAMA|2015|420
Three-Year Update of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia in the ELIANA Trial
|Journal of Clinical Oncology|2022|369